Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBD™
- Development stage
- Preclinical
- Lead developer
- Acumen Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EBD™ (Enhanced Brain Delivery) is a preclinical-stage therapeutic program developed by Acumen Pharmaceuticals in collaboration with JCR Pharmaceuticals. The technology involves the fusion of monoclonal antibodies targeting toxic soluble amyloid beta oligomers (AβOs), such as sabirnetug (ACU193), with transferrin receptor (TfR) binders using JCR's J-Brain Cargo® platform. This approach utilizes receptor-mediated transcytosis to facilitate the transport of the antibody across the blood-brain barrier (BBB), significantly increasing central nervous system (CNS) penetration. Preclinical models have demonstrated a 15 to 68-fold increase in brain uptake compared to conventional antibodies, aiming to improve clinical outcomes in patients with early Alzheimer's disease by achieving higher therapeutic concentrations at the site of pathology.
- Other names
- Enhanced Brain Delivery technologyTfR-targeting AβO antibodyEBD-sabirnetug
02
Targets
Aβ oligomers (Amyloid-β oligomers)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on EBD™.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBD™.